About US
Contact us
-
Pfizer's GSK consumer deal is closed, and generics go next. Will its cash flow recover?The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not2019/8/5
-
After Fresenius deal collapse, Akorn inks $74M settlement with investors over data integrity woesAkorn has had a busy two years in court following a flurry of data integrity woesthat led former merger partner Fresenius to walk away from their deal. Now, it’s putting one issue to rest by settling2019/8/2
-
Takeda whittles away costs—and assets—to keep its debt-cutting promisesTakeda's been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it's on track to hit those goals, executives said this week. The company's cost-saving2019/8/2
-
Pfizer's GSK consumer deal is closed, and generics go next. Will its cash flow recover?The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not2019/8/1
-
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlementsWith Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million could2019/8/1
-
Lilly's Emgality powers ahead with 'best-in-class' CGRP accessEli Lilly’s CGRP migraine prevention drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’sAjovy, but in the second quarter, it gained some steam. By the end of the perio2019/7/31
-
Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn mergerMylan’s EpiPen has had a troubled few years—to say the least—with federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizer's generic business Upjohn work2019/7/31
-
Pfizer points to newer meds—including Ibrance—as post-Upjohn cash enginesOn the heels of news it would spin off its generics wing, Pfizer is looking at a much different future without that $2.8 billion cash engine. But CEO Albert Bourla has a message for investors concern2019/7/30
-
'Autonomous,' yes, but not for sale: Novartis won't sell Sandoz, CEO Vas Narasimhan saysNovartis granting Sandoz independence within the company sounds a lot like what Pfizer did with its own generics business before it struck a deal to merge the unit with Mylan. But to hear Novartis CE2019/7/30
-
Sanofi takes $2B hemophilia write-down as Roche's Hemlibra brings the heatIt’s been just over 16 months since Sanofi closed its $11.6billion buyout of hemophilia specialist Bioverativ. But the company is already revising its sales projections for one of Bioverativ’s key pr2019/7/29